Imagination

Bold Pursuit of New and Better Ways to Transform Health
Moffitt Cancer Center was established in 1981 by the Florida Legislature to address the state’s cancer burden. The center was named after H. Lee Moffitt, former Speaker of the Florida House of Representatives. In 1977, Moffitt lost three friends to cancer — each of whom had to seek sophisticated cancer treatment outside of Florida. Out of Moffitt’s sadness was born a resolve that would direct his efforts for years to come. While serving as speaker of the Florida House of Representatives, Moffitt worked tirelessly to influence legislation that established the cancer center in Tampa.
Dear Friends,

We are pleased to share with you Moffitt Cancer Center’s 2019 Annual Report. This year’s annual report theme – Imagination – touches a broad spectrum of activities related to our mission to contribute to the prevention and cure of cancer. Some might describe imagination as the spark that lights our vision to boldly pursue new and better ways to transform health, wellness and healing.

This report describes the benefits of bringing our scientific discoveries closer to our patients through new and better cures as well as our work in the community to help bring an end to cancer. Highlights of Moffitt’s progress include:

• **Moffitt debuted a new investigative lab test for solid tumors**, Moffitt STAR. The 170-gene panel looks for changes in both tumor DNA and in RNA. As the first institution to develop such a test, Moffitt is helping other cancer centers develop a similar assay. In 2019 Moffitt pathologists will introduce another new assay, the myeloid action panel, or MAP, a 98-gene panel for blood and bone marrow cancers (liquid tumors).

• **Anna Giuliano, PhD, addressed a congressional briefing on human papillomavirus (HPV) and HPV-related cancers.** At the briefing, hosted by U.S. Rep. Kathy Castor, Giuliano stressed the importance of eliminating HPV-related cancers, beginning with cervical cancer, through HPV vaccination.

• **Moffitt invests in its community**, spending a total of $92,479,943 for the cancer center’s Community Benefit programs. These initiatives support patients, families and clinicians through advancing cancer prevention, early detection, clinical care and research, especially for those at-risk populations disproportionately impacted by cancer.

• **Health care disparities is a serious issue** in the Tampa Bay area and beyond, and Moffitt is committed to reducing disparities and working toward closing gaps in health care outcomes. To that end, Susan Vadaparampil, PhD, MPH, was named Moffitt’s first Associate Center Director of Community Outreach, Engagement, & Equity. She will work with the community to better understand how to shape solutions that fit our community.

• **In a new partnership, Moffitt and AdventHealth** are expanding cancer care in the Tampa Bay area and will open a new Moffitt outpatient center on the campus of AdventHealth Wesley Chapel in Pasco County.

As this annual report goes to press, we learned that Moffitt has once again earned the prestigious Magnet designation. Awarded by the American Nurses Credentialing Center, the designation is steadfast proof of a hard-earned commitment to excellence in patient care.

*Alan F. List, MD*  
President and Chief Executive Officer

*Timothy J. Adams*  
Chair
Imagination and Innovation

Key Resources for a Positive Future

Since Moffitt opened its doors in 1986, our patients always have come first, and this commitment remains at the heart of our mission. Last year after embarking on our new strategic plan, IMPACT 2028, we decided to take a closer look at our organizational values to ensure our core beliefs reflect who we are and how we will continue to make an impact in the lives of those affected by cancer – for the next 10 years and beyond. The Moffitt values of compassion, drive, excellence, imagination and inclusion reflect how we are working together to deliver on our mission to contribute to the prevention and cure of cancer. One of these key values, imagination, is described by the Moffitt team this way: “We are bold in our pursuit of new and better ways to transform health, wellness and healing.”
It takes courage and perseverance for patients to reach the point where they can ring the bell to celebrate the completion of treatment. For Stephanie Stanfield, she prefers to celebrate every day of life.

**CELEBRATING THE TREATMENT**

Diagnosed with inoperable stage 4 metastatic breast cancer in 2017, Stanfield is benefiting from the vision and creativity of research scientists and physicians who work to cure cancer and also to offer people with terminal disease like Stanfield a longer and better quality of life.

Working with her doctors at Moffitt, Stanfield has taken steps to improve her immune system as much as possible while undergoing continual treatment. This includes hormone therapy to inhibit the growth and spread of the cancer, as well as oral chemotherapy to slow the progression. Every three months, Stanfield visits Moffitt’s Richard M. Schulze Family Foundation Outpatient Center for treatment with Zometa®, an infusion drug she receives to help strengthen her bones and keep her cancer from spreading.

Known to be a source of positivity to her loved ones, Stanfield recounts her blessings: “I didn’t have to go straight to intravenous chemotherapy. I didn’t lose my hair. I didn’t have the fatigue many people manifest from treatment. And I’m stable.”

Stanfield celebrates every day as a victory. After completing her first infusion cycle, she rang the bell, although she knows she will be on treatment for the rest of her life. “Every month that I start another treatment cycle is a celebration for me.”

Stanfield continues to take advantage of every opportunity to enjoy life. She and her husband made one of their dreams a reality when they recently took a trip of a lifetime to Bora Bora.

**BREAST CELLULAR THERAPY AND VACCINE RESEARCH**

Meanwhile, Moffitt researchers are imagining new therapies to help breast cancer patients like Stanfield. Some of their most promising work involves therapeutic vaccines. While most vaccines protect against diseases like polio or measles, therapeutic vaccines boost a patient’s immune system response to cancer.

For example, patients with HER-2 and triple negative breast cancers may benefit from a vaccine made with their own immune cells. Called a dendritic cell vaccine, this personalized therapy is created from immune cells that help the body recognize and break down cancer cells so that T cells can destroy them.

Another type of therapeutic vaccine is known as a peptide vaccine. The synthetic vaccine teaches the body to recognize cancer cells by exposing the immune system to harmless snippets of viral proteins. Upon vaccination, the body creates T cells that remember these proteins in case they are encountered again. Studies are underway at Moffitt using peptide vaccines in conjunction with Imfinzi (durvalumab), a checkpoint inhibitor that also works to boost the immune system, for patients with triple negative breast cancer.

There is no targeted treatment for triple negative breast cancer, making it a challenge to treat. Moffitt was the first to study a different approach in early stages of this aggressive cancer. A modified form of the herpes simplex 1 virus called talimogene laherparepvec (T-VEC) is injected directly into the tumor during chemotherapy and before surgery. The herpes simplex virus has been genetically modified to selectively replicate in the tumor and cause cancer cell destruction while leaving normal cells alone.

---

**Don Shula Breast Cancer Fund**

**INVEST IN IMAGINATION**

Breast cancer is the second most common cancer among women in the United States and the second leading cause of cancer death in women. The disease represents 15.2% of all new cancer cases in the U.S.

Fortunately, Moffitt is pioneering life-changing cancer treatments that were once not thought possible. But it often takes philanthropic funding to bring the imagination of research scientists and physicians to life as they envision and develop more effective ways to tackle this disease.

A pioneer on the football field, NFL Hall of Famer Don Shula recognized Moffitt as a pioneer in breast cancer research. Through the innovation of Coach Shula, The Shula fund was created to fuel the imaginative ideas of Moffitt physician-scientists that will translate into tomorrow’s new and better treatments.

We invite you to help save lives by investing in imaginative innovation for breast cancer research.

To learn more, please call 813-745-1403, send an email to FoundationInfo@moffitt.org or visit Moffitt.org/give.
“We have the opportunity to eliminate up to six HPV-related cancers in our lifetime, starting with cervical cancer.”

—Dr. Anna Giuliano

“Every two minutes a woman dies of cervical cancer,” Giuliano told the panelists and participants. “This is a completely preventable cancer!”

In 1995, HPV was thought to cause only cervical cancer. In 2005, evidence indicated that HPV causes multiple cancers, including throat cancer. Although screening exists for cervical cancer, no screenings are available for throat and other cancers caused by HPV. The HPV vaccine can prevent these cancers caused by HPV; however, HPV vaccination rates in the U.S. are much lower than the goal set in Healthy People 2020.

“Every one of you has a role to play in our goal. We have the tools to eliminate HPV-related cancers and save lives,” said Castor.

Giuliano’s work has contributed significantly to the understanding of the rate at which HPV infections are acquired and cleared, the proportion that progress to disease and to HPV vaccine protection against multiple diseases in men and women. Her team at Moffitt was involved in research leading to U.S. Food and Drug Administration approval of the Gardasil and Gardasil 9 vaccines against HPV.

MILES FOR MOFFITT

The organizers, participants and supporters of the first Miles for Moffitt event in 2006 shared a vision to raise funds for lifesaving cancer research. That event raised $55,000, which funded the work of two researchers, each with a $27,500 grant. The first event, held on the University of South Florida campus, drew 1,200 participants. Who would have imagined Miles for Moffitt would raise $3.8* million since its inception and would grow to 5,800 loyal participants who helped raise $1.1 million in 2018 alone? Last year, the race moved to downtown Tampa to accommodate the growing number of people who come...
out each year to enjoy the family-friendly community event.

The Miles for Moffitt 2019 goal is to draw 7,500 participants, noted Maria Muller, executive vice president, chief philanthropy officer and Foundation president.

“I think the race is important, not just because of the money raised, but also the awareness of cancer among the public, and the opportunity to highlight prevention and actions people can take,” said Muller.

From 2006 through 2017, 56 pilot research studies have been awarded, and project funding from the 2018 race proceeds will be awarded in October 2019. This funding helps researchers gather preliminary data and develop their discoveries into a proposal that has greater potential to be funded by grant agencies that generally fund more established projects. Over the past 13 years, these Miles for Moffitt pilot studies have gained more than $18 million in additional grant agency support, all set into motion by our participants, sponsors and donors. One such recipient of a Miles for Moffitt Award, Frederick Locke, MD, says the $100,000 award allowed him to initiate a 10-patient clinical trial utilizing a Moffitt-created vaccine against a target called survivin. Survivin is a target that when found in patients’ myeloma cells is predictive of worse outcomes, resistance to chemotherapy and shorter survival. The hope was the vaccine against survivin could potentially improve the outcome of myeloma patients by administering it in conjunction with an autologous stem cell transplant.

After treating the first two patients, the trial was expanded based on the early results. "We have treated 14 patients on the trial, and we now are finishing the manuscript describing those results," said Locke.

In 2015, Locke received a five-year National Cancer Institute grant that is allowing continuation of the work. “Getting the NCI grant was built upon doing the trial,” said Locke. “The Miles for Moffitt grant was integral to my success in obtaining federal funding for ongoing research.”

That initial work with the survivin vaccine, a cellular immunotherapy, also helped lay the foundation for Locke to continue research in cellular immunotherapies. More recently, Locke has been doing much work with CAR T, another cellular therapy. “Although the Miles for Moffitt grant was not centered on CAR T, the funding helped to build momentum in order to continue research in cellular immunotherapies.”

*Editor’s online revision: Miles for Moffitt raised more than $5 million since the event’s inception.

**CAR T PROGRESS AT MOFFITT**

Revolutionary immunotherapies including CAR T are drawing patients to Moffitt from around the globe. In the first seven months of 2019 alone, 83 patients received commercially available CAR T therapies. Another 58 patients were treated with CAR T as part of clinical trials. Also during this timeframe, 14 clinical trial patients have received another cellular immunotherapy called TIL, for tumor infiltrating lymphocytes.
Moffitt Cancer Center has debuted a new investigative lab test, Moffitt STAR, a 170-gene panel that not only looks for changes in tumor DNA like other conventional next generation sequencing tests, but it also investigates changes in RNA, the shorter, single-stranded cousin of DNA. As the first institution to develop such a test, Moffitt has been a leader in this area and is helping other cancer centers develop a similar assay.

"RNA testing opens up a whole new field and we are making discoveries that just haven’t been seen or investigated before," said pathologist Theresa Boyle, MD, PhD, who helped build the new technology from the ground up. “When we make a diagnosis, we can be sure we’ve investigated the patients’ genes for any changes that lend themselves to known treatments. We also have enough information about the patients’ unique genetics to match them to a targeted therapy or to a Moffitt clinical trial aimed at those genetic findings.”

This work is paving the way to a new treatment option for cancer patients. Moffitt STAR can detect fusions at the RNA level that are not accessible through DNA testing, including mutations in messenger RNA (mRNA) that are involved in protein production.

Some of these are first-in-human studies. Patients are often referred from other institutions for these trials because Moffitt has an experienced team, dedicated to immune cell therapies, to select, deliver and manage the care of patients receiving novel therapies through these new approaches.

Moffitt physician-scientists shared their expertise and experience with cellular immunotherapies at the 2019 American Society of Clinical Oncology Annual Meeting, one of the largest annual educational and scientific events in the oncology community. Among more than 30 Moffitt abstracts and presentations at ASCO were:

- Phase 1 results of ZUMA-3, a study of an investigational CAR T cell therapy, in adult patients with relapsed or refractory acute lymphoblastic leukemia, presented by abstract lead author Dr. Bijal Shah.
- A clinical science symposium presentation on the opportunities of CAR T for liquid and solid tumors including sarcoma as well as ovarian, lung, gastric, colorectal and breast cancers, by Dr. Marco Davila
- Preliminary results of a phase 2 clinical trial of tumor infiltrating lymphocytes, or TIL, for patients whose advanced melanoma has not responded to other treatments including PD-1 antibody therapy, presented by lead author Dr. Amod Sarnaik

Study findings presented by Sarnaik showed 38% of trial participants responded to TIL therapy for their advanced melanoma. Some may even have been cured with a single TIL treatment. In TIL, patients whose cancer cannot be cured through surgery have part of their tumor removed to gain access to cancer-fighting immune cells within it. These TIL cells are multiplied in a special processing lab so that billions of them can be infused back into the patient and zero in on the cancer. Moffitt has been working on TIL therapy for more than a decade. Based on the findings presented at ASCO, the FDA will likely be asked to OK the therapy’s widespread use for advanced melanoma.

STAR AND MAP HELP INFORM TREATMENT

Moffitt Cancer Center has debuted a new investigative lab test, Moffitt STAR, a 170-gene panel that not only looks for changes in tumor DNA like other conventional next generation sequencing tests, but it also investigates changes in RNA, the shorter, single-stranded cousin of DNA. As the first institution to develop such a test, Moffitt has been a leader in this area and is helping other cancer centers develop a similar assay.

"RNA testing opens up a whole new field and we are making discoveries that just haven’t been seen or investigated before," said pathologist Theresa Boyle, MD, PhD, who helped build the new technology from the ground up. “When we make a diagnosis, we can be sure we’ve investigated the patients’ genes for any changes that lend themselves to known treatments. We also have enough information about the patients’ unique genetics to match them to a targeted therapy or to a Moffitt clinical trial aimed at those genetic findings.”

This work is paving the way to a new treatment option for cancer patients. Moffitt STAR can detect fusions at the RNA level that are not accessible through DNA testing, including mutations in messenger RNA (mRNA) that are involved in protein production.
Logic will get you from A to B. Imagination will take you everywhere.

— Albert Einstein

Moffitt STAR is a 170-gene panel that looks for changes in both tumor DNA and in RNA. The results can confirm diagnoses and give clear guidance on whether a patient would benefit from a particular treatment. The first institution to develop an integrated DNA- and RNA-based test, Moffitt has been a leader in this area and is helping other cancer centers develop a similar assay.

level, and the results can give clear guidance to doctors on whether a patient would benefit from a particular treatment. Moffitt STAR results not only can guide therapy, but also confirm diagnoses and, on a few occasions, have even overturned a wrong diagnosis. As of July 2019 the test has been used in more than 800 cases.

In 2019 Moffitt pathologists are introducing another new assay that is similar to STAR. The myeloid action panel, or MAP, is a comprehensive 98-gene panel for blood and bone marrow cancers. While Moffitt STAR is used for solid tumors, MAP will be used for liquid ones and has the potential to be one of the best assays in the malignant hematology field.

“RNA testing opens up a whole new field and we are making discoveries that just haven’t been seen or investigated before.”

— Dr. Theresa Boyle
ARTIFICIAL INTELLIGENCE

Several years ago, few people would have imagined that mathematics would be directly involved in cancer prognosis and corresponding treatment. Yet today, Moffitt’s Department of Integrated Mathematical Oncology is well established and is using the power of mechanistic mathematical models to better understand cancer initiation, progression and treatment, and is playing a key role in precision medicine through treatment decision support in a number of ongoing clinical trials.

Similarly, artificial intelligence (AI) is gaining ground in the field of health technology. J. Ross Mitchell, PhD, MSc (pictured here), joined Moffitt in FY 2019 as our first Artificial Intelligence Officer. In this role, Mitchell will lead the cancer center’s efforts to develop digital tools and technologies that utilize computer science to improve the efficiency and quality of cancer care.

“Moffitt is a leader in medical data science and has a long history of using advanced analytics to improve cancer outcomes,” said Mitchell. “With its strategic focus on AI to empower precision medicine, I could not think of a better place to leverage AI to improve the quality and effectiveness of cancer diagnosis and treatment.”

Among clinical projects already underway is a program using natural language processing to extract tumor site and histology information from the free text of pathology reports for use in clinical trial matching, clinical pathways and other decision support tools. Another project involves the development of models for predicting sepsis in cancer patients. Mitchell is also using AI in his own research, including a neuroradiology imaging study that will utilize AI to read brain scans and identify a tumor’s location and volume within minutes.

NCI COMPREHENSIVE CANCER CENTER DESIGNATION

When then-Speaker of the Florida State House H. Lee Moffitt first imagined a cancer center in Tampa to serve all of Florida, he always envisioned that one day it would become a national leader in cancer care and research.

Even he could not foresee how quickly Moffitt Cancer Center would join the National Cancer Institute’s most elite group.

Only 51 centers nationwide have met rigorous standards to be called an NCI Comprehensive Cancer Center. Another 21 cancer centers have successfully achieved NCI designation, but lack the breadth, depth and integration of research to achieve comprehensive status. Moffitt is the only NCI comprehensive cancer center based in Florida.

Moffitt attained comprehensive status in 2001 at a remarkable pace, just three years after achieving NCI designation and 15 years after first opening its doors. Along with designation came the NCI Cancer Center Support Grant (CCSG), which partially underwrites the necessary structure for a collaborative environment where great cancer research can take place.

Once attained, NCI Comprehensive status and CCSG dollars are not assured permanently. Every five years, centers must apply to renew their grant and status. NCI standards change over time to reflect research progress and needs. As part of grant renewal, all NCI centers now must demonstrate how knowledge gained from their research benefits the communities they serve. In response, Moffitt created a new leadership position in Fiscal Year 2019 to help better understand and address our community’s cancer needs through engagement, ongoing dialogue and strong partnerships.
NEW POSITION FOCUSES ON COMMUNITY OUTREACH

Susan Vadaparampil, PhD, MPH (pictured above), is Moffitt’s first Associate Center Director of Community Outreach, Engagement & Equity. She has spent more than 15 years at Moffitt, researching cancer health disparities and participating in community projects that will serve as a solid foundation for the work ahead.

“We need to bring the community to the table,” says Vadaparampil, “to tell us what the most pressing needs are, and to help us understand how to shape solutions that fit our community.”

Though Moffitt sees patients from around the globe, the NCI defines our community as the 15-county catchment area surrounding the cancer center that is home to a majority of its patients. Moffitt’s catchment area is home to 5.8 million people – 30% of the state’s population.

So, how does Moffitt ensure that its research efforts address the needs of people throughout our community?

One of Vadaparampil’s first projects was to form a Research Integration Committee with the aim of supporting ongoing efforts and building additional capacity for catchment area research across all Moffitt Research programs. Along with Moffitt researchers and physicians across numerous disciplines, community members include representatives from the Tampa Bay Community Cancer Network and the Ponce Health Sciences University – Moffitt Cancer Center partnership.

“I don’t pretend to have all the answers for what our priorities should be,” says Vadaparampil. “But I am listening to those who have been doing this work. The next step will be to bring that information back to our community partners so we can maximize Moffitt’s impact in our community and beyond.”

WHERE WILL OUR IMAGINATION TAKE US?

We look forward to initiating even more important scientific research, delivering new and better cancer treatments, and growing our reach to contribute to the prevention and cure of cancer.

We believe the ambitious strategies and goals of IMPACT 2028 will help keep us on course to increase our services and deliver the best outcomes to the Tampa Bay community, Florida and beyond.

Hope lies in dreams, in imagination, and in the courage of those who dare to make dreams into reality.

— Jonas Salk
Community Benefit 2019

Community Benefit Accomplishments

In Fiscal Year 2019, Moffitt Cancer Center completed its final year of the 2016-2019 Implementation Plan.* The content below provides an overview of the progress made toward achieving the goals to address Access to Care and Screening and Prevention.

ACCESS TO CARE

1. Improve access to health-related resources for those in need within the primary service area
   - A searchable, web-based Community Resource Directory was developed to provide Moffitt’s team members with a tool to use when navigating patients and community members in need of services.
   - The database includes approximately 100 community agencies and resources and has had 165 page views from July 2017 to May 2019.

2. Provide increased navigation services for patients and community members
   - A Community Navigator, hired as part of a one-year grant, assisted nearly 50 community members with appointments, Language Services, and transportation during cancer screening and treatment services.

3. Support community advocacy to increase access to transportation
   - Along with other businesses, Moffitt donated $25,000 to the Hillsborough Area Regional Transit Authority (HART) to help fund a new bus route system, the Uptowner, that will circulate USF and neighboring businesses in the university area.

SCREENING AND PREVENTION SERVICES

1. Increase awareness and education of cancer prevention and screening
   - Public Service Announcements (PSAs) featuring celebrities were developed to promote cancer screening for breast, lung, colorectal and prostate cancer. PSAs were distributed through television broadcast and digital platforms, and www.canscreen.org was created for viewers to obtain more information about cancer screenings.

<table>
<thead>
<tr>
<th>Type</th>
<th>Total PSA airings</th>
<th>Impressions</th>
<th>Clicks</th>
</tr>
</thead>
<tbody>
<tr>
<td>TV BROADCAST</td>
<td>719</td>
<td>6.1 million</td>
<td></td>
</tr>
<tr>
<td>DIGITAL TRACKING</td>
<td></td>
<td>1.9 million</td>
<td>9,241</td>
</tr>
<tr>
<td>WEBSITE</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

From September 2017 to May 2019, there were 3,728 total sessions.

(1 session=actively engaged with site during a 30-minute timeframe)

198
Adolescent & Young Adult patients in Sarcoma, Gynecologic Oncology and Neuro-Oncology Clinics

513
Patients in the Head and Neck Clinic

TWO INTERNAL PATIENT NAVIGATORS
assisted patients in overcoming barriers and coordinating clinical care throughout their cancer experience.
11,360 people were educated about cancer prevention and screening during 476 workshops, events, and Facebook Live chats throughout FY2017 to FY2019.

2. Provide increased and/or improved screening and prevention services for lung cancer, breast cancer, prostate cancer and colorectal cancer

- Screening vouchers are offered to uninsured patients who meet specific criteria for lung, breast, prostate and colorectal cancer screenings. Moffitt has offered breast and prostate screening vouchers for uninsured patients since 2011. The colorectal and lung vouchers were made available to the community beginning in FY2018.

### Community Benefit Financials

**YEAR: JULY 1, 2017 TO JUNE 30, 2018**

*Moffitt Cancer Center’s Community Benefit initiative supports patients, families and clinicians through advancing cancer prevention, early detection, clinical care and research, especially for those at-risk populations disproportionately impacted by cancer.*

- **RESEARCH**
  - Clinical and community health research, as well as general health care delivery studies shared with the public and funded by the government or a tax-exempt entity
  - $34,433,282

- **MEDICAID SHORTFALLS**
  - The Medicaid program pays Moffitt less than it costs the organization to provide care to its Medicaid patients
  - $18,497,820

- **COMMUNITY HEALTH IMPROVEMENT SERVICES**
  - Cost of activities and events carried out to improve community health beyond patient care
  - $804,381

- **HEALTH PROFESSIONS EDUCATION**
  - Cost associated with clinical education and training for physicians and medical students not including government funding
  - $15,355,704

- **CHARITY CARE**
  - Total cost of services incurred by Moffitt to provide medical services to patients who are unable to pay
  - $23,221,741

- **COMMUNITY BENEFIT OPERATIONS**
  - Community benefit operations include costs associated with assigned staff and community health needs and/or assets assessment, as well as other costs associated with community benefit strategy and operations
  - $98,980

- **COMMUNITY BUILDING ACTIVITIES**
  - Cost of developing community-building programs and partnerships that address the root causes of health problems and offer the expertise and resources of the health care organization
  - $68,035

*The full report of the 2016-2019 Implementation Plan can be found on Moffitt’s website at https://moffitt.org/publications/community-benefit*
Moffitt Cancer Center is recognized as the model wherein the diversity of our communities and team members is valued and supported as we create a culture of inclusion, which is essential to contributing to the prevention and cure of cancer.

Language Services

Language Services provides timely, centralized, and professional language access to our patients who speak little English or no English and those who are Deaf or Hard-of-Hearing. Moffitt continues to show language access leadership by being the first hospital in Florida to partner with a professional medical interpreter association, the International Medical Interpreters Association, to offer a regional conference. In FY 2019, Moffitt’s Language Services manager, Prado Antolino, received the Distinguished Healthcare Diversity Advocate Award by the National Diversity Council.

<table>
<thead>
<tr>
<th>LANGUAGE SERVICES PERFORMED</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>203</td>
<td>American Sign Language encounters</td>
</tr>
<tr>
<td>120</td>
<td>Discharged instructions translated</td>
</tr>
<tr>
<td>6,705</td>
<td>Spanish in-house encounters completed</td>
</tr>
<tr>
<td>29</td>
<td>Informed consents translated</td>
</tr>
<tr>
<td>843</td>
<td>Translations completed into Spanish</td>
</tr>
</tbody>
</table>

M-POWER

M-POWER provides health education to at-risk communities on cancer screening and early detection. This year’s focus was on educating community members who were within the recommended screening age range of 21-69 years. Pap and HPV tests begin at 21; mammograms at 40; colonoscopies at 50; and lung and prostate exams beginning at 55, with prostate ending at 69 years of age. Participants were also encouraged to adhere to their medical professional’s recommendations because their health history or condition may require screening at an earlier age. In 2019 80% of the workshop participants were within the recommended screening ages, compared to 53% in 2018.
Diversity and Inclusion

Commitment to diversity and inclusion is embedded in Moffitt Cancer Center’s culture and demonstrated in the daily work of cancer center team members.

Moffitt has partnered in a work-force training and readiness program and employment pipeline with the MacDonald Training Center, a Tampa, Florida-based nonprofit, with a mission to empower people with disabilities. The joint initiative provides vocational training in environmental services (ES). As part of the partnership, Moffitt has opened a replica patient room for simulation training. Trainees will learn in the context of the hospital and health care environment and the learned skills can transfer to a variety of other environments, including hospitality.

Moffitt hosted an awareness seminar focused on best practices for lesbian, gay, bisexual, transgender and queer/questioning (LGBTQ) people with cancer.

FY2019 DIVERSITY & INCLUSION RECOGNITIONS:

- DiversityInc’s #3 Top Hospitals and Health Systems
- Leading Employer, Veteran Friendly Employer
- Leading Employer, National Organization on Disabilities
- Disability Matters, Steps-to-Success Award
- Human Rights Campaign, Leader in LGBTQ Healthcare Equality for eight consecutive years

TEAM MEMBER ENGAGEMENT NETWORKS

Moffitt has two TMENs: Generation Moffitt (GenM), which supports young cancer center professionals, and Unity@ Moffitt, which includes lesbian, gay, bisexual, transgender, queer and ally (LGBTQA+) members. TMEN welcomed an Executive Sponsor to serve as a catalyst and to ensure continued success. With the help of this leadership guidance, the networks are poised to achieve their missions and visions.

Supplier Diversity

Moffitt welcomes the opportunity to develop mutually beneficial business relationships with qualified diverse businesses.

MENTOR PROTÉGÉ SPOTLIGHT

Moffitt’s focus on inclusion resulted in a new Mentor Protégé relationship between Creative Contractors, the design-builder responsible for construction of the Clinic Support Building, and Kenstruction Dynamics, a local certified Minority Business Enterprise. Working with Creative Contractors, the Kenstruction Dynamics team has been able to gain valuable construction experience.

FY2019 DIVERSITY & INCLUSION RECOGNITIONS:

- DiversityInc’s #3 Top Hospitals and Health Systems
- Leading Employer, Veteran Friendly Employer
- Leading Employer, National Organization on Disabilities
- Disability Matters, Steps-to-Success Award
- Human Rights Campaign, Leader in LGBTQ Healthcare Equality for eight consecutive years

TEAM MEMBER ENGAGEMENT NETWORKS

Moffitt has two TMENs: Generation Moffitt (GenM), which supports young cancer center professionals, and Unity@ Moffitt, which includes lesbian, gay, bisexual, transgender, queer and ally (LGBTQA+) members. TMEN welcomed an Executive Sponsor to serve as a catalyst and to ensure continued success. With the help of this leadership guidance, the networks are poised to achieve their missions and visions.

Supplier Diversity

Moffitt welcomes the opportunity to develop mutually beneficial business relationships with qualified diverse businesses.

MENTOR PROTÉGÉ SPOTLIGHT

Moffitt’s focus on inclusion resulted in a new Mentor Protégé relationship between Creative Contractors, the design-builder responsible for construction of the Clinic Support Building, and Kenstruction Dynamics, a local certified Minority Business Enterprise. Working with Creative Contractors, the Kenstruction Dynamics team has been able to gain valuable construction experience.

FY2019 DIVERSITY & INCLUSION RECOGNITIONS:

- DiversityInc’s #3 Top Hospitals and Health Systems
- Leading Employer, Veteran Friendly Employer
- Leading Employer, National Organization on Disabilities
- Disability Matters, Steps-to-Success Award
- Human Rights Campaign, Leader in LGBTQ Healthcare Equality for eight consecutive years

TEAM MEMBER ENGAGEMENT NETWORKS

Moffitt has two TMENs: Generation Moffitt (GenM), which supports young cancer center professionals, and Unity@ Moffitt, which includes lesbian, gay, bisexual, transgender, queer and ally (LGBTQA+) members. TMEN welcomed an Executive Sponsor to serve as a catalyst and to ensure continued success. With the help of this leadership guidance, the networks are poised to achieve their missions and visions.

Supplier Diversity

Moffitt welcomes the opportunity to develop mutually beneficial business relationships with qualified diverse businesses.

MENTOR PROTÉGÉ SPOTLIGHT

Moffitt’s focus on inclusion resulted in a new Mentor Protégé relationship between Creative Contractors, the design-builder responsible for construction of the Clinic Support Building, and Kenstruction Dynamics, a local certified Minority Business Enterprise. Working with Creative Contractors, the Kenstruction Dynamics team has been able to gain valuable construction experience.
Highlights 2019

SUCCESSFUL YEAR FOR THE MOFFITT FOUNDATION

Our community of more than 26,000 donors gave $27 million to Moffitt to support cancer care, research and educational outreach efforts.

Support included significant funds for areas of greatest need such as research, patient care initiatives and capital improvement projects, as well as endowments and planned gifts that will help keep Moffitt at the forefront of life-changing cancer treatments and programs.

Our donors supported the research being done in departments across Moffitt, including Integrated Mathematical Oncology, as well as melanoma, thoracic, hematology and genitourinary oncology.

More than 80 events were hosted this fiscal year by dedicated community partners, who together raised more than $1.1 million for Moffitt. Events like Martinis for Moffitt, Swim Across America, Skanska’s Hooked on a Cure Fishing Tournament, Callaghan Pro-Am Golf Tournament, Amandalee Golf Classic, Dawn Coe-Jones Golf Classic, Golfers vs. Brain Cancer and Buffalo Wild Wings’ May promotional activities were just a few of the community partners who were instrumental in raising funds to support Moffitt.

26TH ANNUAL MAGNOLIA BALL

On April 27, more than 700 guests attended the 26th Magnolia Ball at the Tampa Marriott Water Street.

MILES FOR MOFFITT

Since 2006, the annual Miles for Moffitt event has brought together thousands of runners, walkers, wheelchair racers, volunteers, survivors, caregivers, supporters and friends in a courageous community effort to end cancer. The 2018 Miles for Moffitt – held for the first time in downtown Tampa – raised more than $1.1 million and drew 5,800 participants, including 1,000-plus Moffitt employees. Participants and sponsors of this event help save lives and bring us closer to achieving our mission to contribute to the prevention and cure of cancer. Mark your calendar for this year’s Miles for Moffitt, on Nov. 23, in downtown Tampa. Register today at MilesforMoffitt.com.

SENIORS EXCELLING IN STEAM RECEIVE HEALTHY KIDZ SCHOLARSHIPS

Moffitt’s Healthy KidZ program presented 12 scholarships for $2,000 each for higher education to graduating seniors who excel in STEAM (science, technology, engineering, arts and math). The community outreach program is targeted to children and adolescents focusing on cancer prevention, healthy living and careers in STEAM. This is the third consecutive year Moffitt Healthy KidZ has offered Role Model Scholarship awards.

MOFFITT’S CHIEF INFORMATION SECURITY OFFICER ENCOURAGES ACTION TO STOP ROBOCALLS

Dave Summitt, Moffitt’s chief information security officer, testified before a congressional committee encouraging action to stop spam callers that target health care facilities and threaten patient’s safety across the country. His testimony was a part of the House Energy and Commerce Committee hearing on several pieces of legislation to crack down on scam callers.

Summitt asked Congress to consider changes to improve anti-robocall legislation, including:

- Require accurate caller identification.
- Hold telecommunications carriers responsible, at least in part, for cracking down on robocalls.
- Require telecommunications carriers to work with businesses to investigate and stop malicious activity.

Summitt’s testimony was signed by health care systems across nine states and Washington, D.C.
GOVERNMENT RELATIONS – STATE AND MOFFITT DAY

The Florida Legislature convened in March and April for the 2019 regular legislative session. The Legislature prioritized funding initiatives that directly impacted Moffitt Cancer Center, biomedical research and patient access to cancer screenings and treatment.

The Government Relations team was effective in maintaining this source of state funding for cancer research. Since this program's inception, Moffitt has been able to recruit and create over 100 full-time research positions. The team successfully secured funding in the education portion of the state budget, which helps supplement the training of over 2,000 students and future oncology professionals, and maintained our portion of the cigarette tax funds, which are used for construction and capital outlay.

Finally, for Medicaid purposes, we were instrumental in successfully passing legislation, which fortified Moffitt’s status as a Specialty Cancer Center in statute while securing an additional appropriation in Low Income Pool funding of $11 million. These accomplishments ensure Moffitt is adequately reimbursed for our care.

Also, the Biomedical Research Programs, which provide researchers at Moffitt with an opportunity to compete for funding, were fully funded, with $10 million each in the James and Esther King and Bankhead-Coley Research Programs, and an additional investment of $3 million in recurring funds for pediatric cancer research. The Florida Academic Cancer Center Alliance received an appropriation of $60 million. Moffitt directly receives a portion of these funds.

GOVERNMENT RELATIONS – FEDERAL

Moffitt took a leadership role in advocating for patient access to CAR T treatment, a new mode of immunotherapy that is saving the lives of many patients who have exhausted other treatment options. Moffitt leaders helped high-ranking members of the presidential administration and the Florida congressional delegation to understand the value of CAR T therapy so that it would be covered through the Medicare program with sufficient reimbursement for the hospitals that provide it.

Moffitt continued to receive recognition from Congress this year for our partnerships to improve cancer outcomes for active duty and retired military members. Through Moffitt’s advocacy, the House Appropriations Committee has directed the Secretary of the U.S. Veterans Administration to invest in partnerships with National Cancer Institute-designated centers like Moffitt to provide clinical trials for veterans with cancer.

Moffitt leaders provided expert testimony in a number of congressional hearings and briefing events. Topics included the goal of eliminating cervical cancer and other cancers related to human papillomavirus, the effect of e-cigarettes on nicotine addiction and the threat of robocalls on health information systems and patient safety.

SPRING SWING® – MOFFITT’S SUN SAFETY TOUR OFFERS FREE SKIN SCREENINGS AT BALLPARKS

Spring Swing® – Moffitt’s Sun Safety Tour, a partnership between Moffitt and the Tampa Bay Rays, offered free skin cancer screenings at specified baseball spring training venues throughout Florida.

Now in its 12th year, Spring Swing has provided 4,754 free skin screenings where skin cancer experts detected 4,865 suspicious findings (some people screened had multiple suspicious lesions). The lesions included 26 suspected melanomas, which is the deadliest form of skin cancer but it often is curable if detected and treated early.

RECORD NUMBERS ATTEND BUSINESS OF BIOTECH CONFERENCE

Artificial intelligence, cell therapy, clinical pathways and immune oncology production were spotlighted at another successful installment of Moffitt Cancer Center’s Business of Biotech Conference: Cracking the Cancer Code. The 13th annual conference held Feb. 22 had a record-breaking number of 21 sponsors, 60 partnering meetings and more than 450 people attending from biotech companies, universities, startups, investors and entrepreneurs from around the globe.
NEW MOFFITT OUTPATIENT CENTER TO OPEN AT ADVENTHEALTH

Moffitt and AdventHealth are expanding cancer care in the Tampa Bay area and will open a new Moffitt outpatient center on the campus of AdventHealth Wesley Chapel in Pasco County. The new center opens in fall 2020 and will provide medical and radiation oncology services and is designed to accommodate 20 exam rooms, 22 infusion stations and two linear accelerators. Cancer screenings and survivorship programs geared toward patients who are post-treatment and in remission will also be available.

TUHURA BIOPHARMA PARTNERSHIP FOCUSES ON TARGETED IMMUNOTHERAPIES

Moffitt announced a licensing agreement with TuHURA Biopharma Inc. to develop new immunotherapy treatments for cancer that will apply to a greater number of cancers and a larger patient population. Moffitt researchers identified a cellular target that, when blocked, decreases the immune suppressing capabilities of the tumor microenvironment—the immediate area surrounding a tumor, including blood vessels, supporting cells and immune cells. By impacting the tumor’s microenvironment, tumors become more vulnerable to attack by a patient’s immune system. The approach targets immunotherapy directly to cancer cells, with less toxicity and less severity of side effects.

MULTIVIR, MOFFITT WORK ON CANCER VACCINE

Moffitt and MultiVir Inc. entered into a licensing agreement, working to develop a personalized cancer vaccine that targets the p53 genetic mutation commonly found in cancers. The Ad-p53 Dendritic Cell Vaccine is an investigational immunostimulatory therapy jointly invented by Moffitt scientists and investigators at MultiVir. Its goal is to activate cancer-fighting immune cells to target the abnormal tumor suppressor p53 that is overexpressed in nearly 50% of all cancers. This investigational therapy could provide a new approach for patients with relapsed/recurrent small cell lung cancer. If there is success in small cell lung cancer, there could be an opportunity to expand the vaccine’s use for other cancers, noted Alberto A. Chiappori MD, co-principal investigator of the clinical trial.

GRANT FUNDING

Project funding is critical to the success of cancer research. Highlights of a few key grants received in 2019 appear below.

KAY YOW FUNDS OVARIAN CANCER RESEARCH

The Kay Yow Cancer Fund granted $100,000 for ovarian cancer research to Moffitt immunologists Paulo C. Rodriguez, PhD, and Jose R. Conejo-Garcia, MD, PhD. Conejo-Garcia, who chairs Moffitt’s Department of Immunology, voiced the expectation that research funded by this grant ultimately will result in the first FDA approval of a CAR T therapy for solid tumors, thus making the immune system more effective in ovarian cancer patients as well as resulting in increased effectiveness through better targeting strategies. New therapies for ovarian cancer are needed because the disease often is diagnosed at an advanced stage.

NCI FUNDS MULTIPLE MYELOMA RESEARCH

Conor C. Lynch, PhD, of Moffitt’s Tumor Biology Department, received a $2.2 million National Cancer Institute R01 award for his research project, “Local and systemic control of multiple myeloma colonization and growth by MMP-13.” Lynch and his team will explore the role of a bone-derived enzyme in multiple myeloma progression. The new R01 award spans five years and is an example of the interdisciplinary team science at Moffitt.

CANCER CHEMOPREVENTION

Nagi Kumar, PhD, RD, FADA, was granted a $3,055,214 five-year R01 award by the National Cancer Institute for her research project, titled “Phase II Clinical Trial of GTC [green tea catechins] in Men on Active Surveillance.” Kumar will work with co-investigators Michael Schell, Christine Pierce, Jasreman Dhillon, Shohreh Dickinson, Kosj Yamoah, Brandon Manley, Michael Poch, and Julio Pow-Sang on the project.
Moffitt’s Chief Financial & Administrative Officer, Yvette Tremonti, participated in and won The Leukemia and Lymphoma Society Woman of the Year contest. She raised $256,000, far surpassing her original fundraising goal of $100,000.

Dave Summitt, Moffitt’s chief information security officer, was named a Fellow of the Institute for Critical Infrastructure Technology (ICIT), the nation’s leading cybersecurity think tank. ICIT provides objective, nonpartisan advisory to the Senate, House of Representatives, and federal government leaders in civilian, defense and intelligence agencies.

Robert Gillies, PhD, chair of Moffitt’s Cancer Physiology Department and vice chair of Radiology Research, received the 2018 Gold Medal Award by the World Molecular Imaging Society. The World Molecular Imaging Society is a scientific educational organization dedicated to the understanding of biology and medicine. Gillies and his team investigate cancer through multiple approaches such as radiomics and cellular biology.

Alan List, MD, president and CEO of Moffitt Cancer Center, is being inducted into the 2019 Florida Inventors Hall of Fame, which recognizes and honors inventors dedicated to advancing the quality of life for Floridians. Additionally, List was selected as a resident member of The Florida Council of 100, a private, nonprofit, bipartisan organization that promotes the economic growth of Florida.

Moffitt’s Faculty, Team Members Are Acknowledged

Best Hospitals list for 20 years in a row. U.S. News evaluated more than 4,500 medical centers nationwide in 25 specialties, procedures and conditions.

NAFE Names Moffitt A Top Nonprofit For Executive Women

Moffitt was named a 2019 NAFE [National Association for Female Executives] Top 10 Nonprofit Company for Executive women, appearing for the 10th time on the list, which recognizes organizations that identify and advance women through their ranks. The announcement was featured in the April/May issue of Working Mother. This list recognizes U.S. nonprofit organizations with a strong focus on best practices that demonstrate effectiveness in moving women to senior ranks, including mentoring, sponsorship, involvement in employee resource groups and leadership development training.

Press Ganey Guardian of Excellence

For the fourth consecutive year, Moffitt was recognized as a winner of the Press Ganey Guardian of Excellence Award, announced in late 2018. The award is a nationally recognized symbol of achievement in health care, acknowledging commitment to offering an exceptional patient experience. Press Ganey is recognized as a pioneer and thought leader in patient experience measurement and performance improvement solutions.

Computerworld Names Moffitt To Best Places To Work In IT

For the second year in a row Computerworld magazine ranked Moffitt as 31 on its list of top 100 Best Places to Work in IT 2019. The ranking is based on company offerings in categories such as benefits, career development, training and retention as well as extensive surveys with IT employees.

Moffitt Named A Tampa Bay Times Top Workplace For The Ninth Time

Again in 2019, for the ninth time, Moffitt was named one of the Tampa Bay Times Top Workplaces. The Top Workplaces list is based solely on employee feedback gathered through a third-party survey administered by the Tampa Bay Times’ research partner Energage, LLC, a leading provider of technology-based employee engagement tools.

Moffitt continued to receive several accolades recognizing the cancer center’s commitment to diversity and inclusion and people with disabilities. To find out more, please see the Moffitt Diversity section of this annual report, beginning on Page 14.
Board of Directors

H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC.

Timothy J. Adams, Chair
Beth A. Houghton, Vice Chair
Carlos Alfonso
Angela Biever
The Honorable Carl Carpenter, Jr.
Steven Currall, PhD
Edward DeBartolo
Edward C. Droste
Geoffrey M. Duyk, PhD, MD
Celia D. Ferman
Valerie Goddard
Reginald Goins
The Honorable John A. Grant
Benjamin H. Hill, III, Esq.
The Honorable H. Lee Moffitt
John Ramlil
Francisco J. Sánchez
Liz Smith
Pamela L. Stewart
John A. Tomlin

H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE HOSPITAL, INC.

Beth A. Houghton, Chair
The Honorable Mark A. Pizzo, Vice Chair
Michael O. Bice
Joseph Caballero
Roland Daniels
Valerie Goddard
Robert “Bill” Horton
Jacqueline McGregor Lewis
Jo Manion, PhD
Jennifer Moffitt, PhD
Kevin M. Plummer
Nicolas C. Porter
Mary Anne Reilly
Beth E. Simonetti
Supriya Taneja, Esq.
H. M. “Hal” Walker II, MD

H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE FOUNDATION, INC.

Edward C. Droste, Chair
Peter T. Kirkwood, Esq., Vice Chair
Kiersten L. Allen
Paul Anderson
Carmen Barkett
Christopher W. Boss, Esq.
William Brand
Joseph Caballlero
The Honorable Monterey Campbell
Ronald J. Campbell

Peter Campo, PhD
Eileen Sena Curd
Robert M. Dutkowsky
S. Katherine Frazier, Esq.
Richard Gonzi
Shay Griese
Benjamin H. Hill, III, Esq.
Sean Hyer
Frederick J. Lynch
The Honorable H. Lee Moffitt
Jim U. Morrison
Jim Overton
Rose Baker Reilly
Barbara Ryals
Lansing Scriven, Esq.
Patrick Sobers
Kim A. Sweeners
Don W. Wallace
Julie Wooley

MOFFITT MEDICAL GROUP

Allan S. Martin, Chair
Frank Capitano, Vice Chair
Timothy J. Adams
Joedreica Brown Speights, MD
Hugo Fernandez, MD
Reginald Goins
Nikhil Khushalani, MD
Martha Truslow Lanahan
The Honorable H. Lee Moffitt
Michael J. O’Malley
Robert J. Perez, DDS, FAGD
The Honorable Mark A. Pizzo
Sharmila Seth
Mark Watson
Victor Young

M2GEN®

William S. Dalton, PhD, MD, Executive Chair
Timothy J. Adams
James M. Asher
Helge Bastian, PhD
Peter J. Campo, PhD
Gregory Donn, MD
Alan F. List, MD
Frederick J. Lynch
Richard P. Malloch
Allan S. Martin
Raphael E. Pollock, MD, PhD, FACS, Board Observer
Thomas A. Sellers, PhD, MPH
Steven R. Swartz, Board Observer

Board of Directors and Board of Advisors listing effective July 1, 2019

Board of Advisors

BOB GRIESE
Chair, Moffitt Board of Advisors
Miami Dolphins Radio Analyst
Member, College and Pro Football Halls of Fame

PAUL ANTHONY
Singer, Songwriter, Producer, Transformational Speaker and Celebrity Health Champion

AMY BAKER
Co-Founder and Managing Partner, WINSTON | BAKER

GARY BETTMAN
Commissioner, National Hockey League

FRANCIS T. BORKOWSKI, PhD
Former Chancellor, Appalachian State University; Former President, University of South Florida

SHELLEY BROADER
Retail Executive

KIM CASIANO
President, Kimberly Casiano & Associates, Inc.

DAVID S. CHERNOW
President and Chief Executive Officer, Select Medical Corporation

ROBIN COOK, MD
Physician and Author

THEODORE J. COUCH, SR.
Retired Banker & Philanthropist

SAM DONALDSON
Former ABC News Correspondent; Chair Emeritus, Board of Advisors

EDWARD C. DROSTE
Chairman, Provident Management Corporation

VIVICA A. FOX
Actress, Producer and Philanthropist

NEWT GINGRICH
Former Speaker of the U.S. House of Representatives

BRYAN GLAZER
Co-Chairman, Tampa Bay Buccaneers

SENATOR BOB GRAHAM
Former U.S. Senator; Former Governor of Florida

BRIAN GRIESE
College Football Analyst, ABC/ESPN; Founder & President, Judith Ann Griese Foundation

SCOTT HAMILTON
Olympic Champion, Television Broadcaster, Humanitarian, Motivational Speaker, Author and Cancer Survivor

MIKE JACKSON
Executive Chairman, AutoNation, Inc.

PHIL JONES
Former Correspondent, CBS News

LESA FRANCE KENNEDY
CEO and Vice Chairperson of the Board of Directors, International Speedway Corporation (ISC); Vice Chairperson of NASCAR
INTERNAL LEADERSHIP

President and Chief Executive Officer
ALAN F. LIST, MD

Center Director and Executive Vice President
THOMAS A. SELLERS, PHD, MPH

EXECUTIVE VICE PRESIDENTS

L. DAVID DE LA PARTE, ESQ.
General Counsel

JOHN A. KOLOSKY, CPA, MBA
Chief Operating Officer
President, Moffitt Hospital

G. DOUGLAS LETSON, MD
Physician-in-Chief, President, Moffitt Medical Group

MARIA MULLER
Chief Philanthropy Officer
President, Moffitt Foundation

YVETTE TREMONTI, CPA, MBA
Chief Financial and Administrative Officer

ASSOCIATE CENTER DIRECTORS

JOHN CLEVELAND, PHD
Basic Science

JAMES J. MULÉ, PHD
Translational Science

DANA ROLLISON, PHD
Data Science
Vice President, Chief Data Officer

BRIAN C. SPRINGER, MHA
Research Administration
Vice President

DANIEL M. SULLIVAN, MD
Clinical Science

SHELLEY TWORODGER, PhD
Population Science

SUSAN VADAPARAMPLIL, PhD, MPH
Community Outreach, Engagement & Equity

EMERITUS

SENATOR BOB DOLE
Special Counsel, Alston & Bird; Former U.S. Senator

SIDNEY KIMMEL
Founder & Chairman, Jones Apparel Group;
Chairman, Sidney Kimmel Foundation

TOM O’BRIEN
Retired President & Chief Executive Officer,
AAA Auto Club South

“Your need imagination in order to imagine a future that doesn’t exist.”

– Azar Nafisi
# Internal Leadership continued

## RESEARCH DEPARTMENTS

<table>
<thead>
<tr>
<th>Department</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BIOSTATISTICS AND BIOINFORMATICS</strong></td>
<td>Brooke L. Fridley, PhD</td>
</tr>
<tr>
<td>Department Chair</td>
<td></td>
</tr>
<tr>
<td><strong>CANCER EPIDEMIOLOGY</strong></td>
<td>Peter Kanetsky, PhD, MPH</td>
</tr>
<tr>
<td>Department Chair</td>
<td></td>
</tr>
<tr>
<td><strong>CANCER PHYSIOLOGY</strong></td>
<td>Robert J. Gillies, PhD</td>
</tr>
<tr>
<td>Department Chair</td>
<td></td>
</tr>
<tr>
<td><strong>DRUG DISCOVERY</strong></td>
<td>Derrick Duckett, PhD</td>
</tr>
<tr>
<td>Department Chair</td>
<td></td>
</tr>
<tr>
<td><strong>HEALTH OUTCOMES AND BEHAVIOR</strong></td>
<td>Thomas H. Brandon, PhD</td>
</tr>
<tr>
<td>Department Chair</td>
<td></td>
</tr>
<tr>
<td><strong>IMMUNOLOGY</strong></td>
<td>José R. Conejo-Garcia, MD, PhD</td>
</tr>
<tr>
<td>Department Chair</td>
<td></td>
</tr>
<tr>
<td><strong>INTEGRATED MATHEMATICAL ONCOLOGY</strong></td>
<td>Alexander Anderson, PhD</td>
</tr>
<tr>
<td>Department Chair</td>
<td></td>
</tr>
<tr>
<td><strong>MOLECULAR ONCOLOGY</strong></td>
<td>Elsa Flores, PhD</td>
</tr>
<tr>
<td>Department Chair</td>
<td></td>
</tr>
<tr>
<td><strong>TUMOR BIOLOGY</strong></td>
<td>Srikumar Chellappan, PhD</td>
</tr>
<tr>
<td>Department Chair</td>
<td></td>
</tr>
</tbody>
</table>

## CCSG PROGRAMS AND LEADERSHIP AREAS

<table>
<thead>
<tr>
<th>Program</th>
<th>Leader(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CANCER BIOLOGY AND EVOLUTION</strong></td>
<td>Elsa Flores, PhD</td>
</tr>
<tr>
<td>Program Leader</td>
<td></td>
</tr>
<tr>
<td><strong>CANCER EPIDEMIOLOGY</strong></td>
<td>Peter Kanetsky, PhD, MPH</td>
</tr>
<tr>
<td>Program Leader</td>
<td></td>
</tr>
<tr>
<td><strong>CHEMICAL BIOLOGY AND MOLECULAR MEDICINE</strong></td>
<td>Derrick Duckett, PhD, Jhanelle Gray, MD</td>
</tr>
<tr>
<td>Department Chairs</td>
<td></td>
</tr>
<tr>
<td><strong>CANCER RESEARCH CAREER DEVELOPMENT &amp; EDUCATION</strong></td>
<td>Kenneth Wright, PhD, Director</td>
</tr>
<tr>
<td>Program Co-Leaders</td>
<td></td>
</tr>
<tr>
<td><strong>HEALTH OUTCOMES AND BEHAVIOR</strong></td>
<td>Thomas H. Brandon, PhD, Heather Jim, PhD</td>
</tr>
<tr>
<td>Program Co-Leaders</td>
<td></td>
</tr>
</tbody>
</table>

## RESEARCH EXTERNAL PARTNERSHIPS

- Jennifer Videau, PhD, MS, Assistant Center Director

## CENTERS OF EXCELLENCE AND INSTITUTES

**IMMUNOLOGY**
- José R. Conejo-Garcia, MD, PhD
- Frederick Locke, MD
  - Program Co-Leaders

**CENTERS OF EXCELLENCE AND INSTITUTES**

<table>
<thead>
<tr>
<th>Center Name</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CENTER FOR IMMUNIZATION AND INFECTION</strong></td>
<td>Anna R. Giuliano, PhD, Shari Pilon-Thomas, PhD, Co-Director</td>
</tr>
<tr>
<td><strong>DONALD A. ADAM MELANOMA AND SKIN CANCER CENTER OF EXCELLENCE</strong></td>
<td>Keiran S. Smalley, PhD, Kenneth Tsai, PhD, Co-Director</td>
</tr>
<tr>
<td><strong>EVOLUTIONARY THERAPY CENTER OF EXCELLENCE</strong></td>
<td>Alexander Anderson, PhD, Robert Gatesby, MD, Co-Director</td>
</tr>
<tr>
<td><strong>LUNG CANCER RESEARCH CENTER OF EXCELLENCE</strong></td>
<td>Eric B. Haura, MD, Director</td>
</tr>
<tr>
<td><strong>DEBARTOLO FAMILY PERSONALIZED MEDICINE INSTITUTE</strong></td>
<td>Howard McLeod, PharmD, Tim Kubal, MD, Co-Director</td>
</tr>
</tbody>
</table>

## CHIEF ACADEMIC OFFICER

- Jonathan S. Zager, MD

## DIVISION OF CLINICAL SCIENCES

<table>
<thead>
<tr>
<th>Specialization</th>
<th>Chair(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANESTHESIOLOGY</strong></td>
<td>David Thrush, MD, Department Chair</td>
</tr>
<tr>
<td><strong>BLOOD &amp; MARROW TRANSPLANT &amp; CELLULAR IMMUNOTHERAPY</strong></td>
<td>Hugo Fernandez, MD, Department Co-Chair (interim), Daniel M. Sullivan, MD, Department Co-Chair (interim)</td>
</tr>
<tr>
<td><strong>BREAST ONCOLOGY</strong></td>
<td>Brian Czerniecki, MD, PhD, Department Chair</td>
</tr>
<tr>
<td><strong>CUTANEOUS ONCOLOGY</strong></td>
<td>Vernon Sondak, MD, Department Chair</td>
</tr>
<tr>
<td><strong>DIAGNOSTIC IMAGING AND INTERVENTIONAL RADIOLOGY</strong></td>
<td>Robert Gatesby, MD, Department Chair</td>
</tr>
<tr>
<td><strong>GASTROINTESTINAL ONCOLOGY</strong></td>
<td>Jason Fleming, MD, Department Chair</td>
</tr>
<tr>
<td><strong>GENITOURINARY ONCOLOGY</strong></td>
<td>Julio Pow-Sang, MD, Department Chair</td>
</tr>
<tr>
<td><strong>GYNECOLOGIC ONCOLOGY</strong></td>
<td>Robert Wenham, MD, MS, Department Chair</td>
</tr>
<tr>
<td><strong>HEAD AND NECK-ENDORCINE ONCOLOGY</strong></td>
<td>Christine H. Chung, MD, Department Chair</td>
</tr>
<tr>
<td><strong>ENDOCRINE ONCOLOGY PROGRAM</strong></td>
<td>Julie Hallanger-Johnson, MD, Program Leader</td>
</tr>
<tr>
<td><strong>INDIVIDUALIZED CANCER MANAGEMENT</strong></td>
<td>Howard McLeod, PharmD, Department Chair</td>
</tr>
<tr>
<td><strong>ADOLESCENT AND YOUNG ADULT PROGRAM</strong></td>
<td>Damon Reed, MD, Program Leader</td>
</tr>
<tr>
<td><strong>GENETICS PROGRAM</strong></td>
<td>Howard McLeod, PharmD, Program Leader</td>
</tr>
<tr>
<td><strong>SUPPORTIVE CARE MEDICINE</strong></td>
<td>Diane Portman, MD, Department Chair</td>
</tr>
<tr>
<td><strong>THORACIC ONCOLOGY</strong></td>
<td>Eric Haura, MD, Department Chair (Interim)</td>
</tr>
</tbody>
</table>

## “Live out of your imagination, not your history.”  
- Stephen Covey
Patient Care Highlights

Moffitt offers a level of service that stands above the rest. Each year, thousands of patients walk through our doors seeking personalized, compassionate care and hope. We are 100% focused on cancer care, and for our patients, this means better outcomes and the best chance for beating cancer.

2019 Patient Care Volumes

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Beds</td>
<td>206</td>
</tr>
<tr>
<td>New Patients</td>
<td>23,760</td>
</tr>
<tr>
<td>Outpatient Visits</td>
<td>450,116</td>
</tr>
<tr>
<td>Admissions</td>
<td>9,465</td>
</tr>
<tr>
<td>Surgical Cases</td>
<td>11,601</td>
</tr>
<tr>
<td>Patients seen</td>
<td>68,148</td>
</tr>
</tbody>
</table>

2019 Payer Mix

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial</td>
<td>1%</td>
</tr>
<tr>
<td>HMO/PPO</td>
<td>41%</td>
</tr>
<tr>
<td>Medicaid</td>
<td>2%</td>
</tr>
<tr>
<td>Medicaid Managed Care</td>
<td>3%</td>
</tr>
<tr>
<td>Medicare</td>
<td>35%</td>
</tr>
<tr>
<td>Medicare Managed Care</td>
<td>14%</td>
</tr>
<tr>
<td>Other</td>
<td>2%</td>
</tr>
<tr>
<td>Private Pay</td>
<td>2%</td>
</tr>
</tbody>
</table>

2019 Patient Origin

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hillsborough</td>
<td>29%</td>
</tr>
<tr>
<td>Pinellas</td>
<td>13%</td>
</tr>
<tr>
<td>Pasco</td>
<td>10%</td>
</tr>
<tr>
<td>Polk</td>
<td>6%</td>
</tr>
<tr>
<td>Manatee</td>
<td>4%</td>
</tr>
<tr>
<td>Sarasota</td>
<td>4%</td>
</tr>
<tr>
<td>Lee</td>
<td>3%</td>
</tr>
<tr>
<td>Other Florida</td>
<td>28%</td>
</tr>
<tr>
<td>Non Florida</td>
<td>3%</td>
</tr>
</tbody>
</table>

2018 12 Most Frequent Cancer Sites*

<table>
<thead>
<tr>
<th>Cancer Site</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>12.9%</td>
</tr>
<tr>
<td>Skin**</td>
<td>9.5%</td>
</tr>
<tr>
<td>Hemeretic</td>
<td>8.7%</td>
</tr>
<tr>
<td>Lung/Bronchus</td>
<td>8.5%</td>
</tr>
<tr>
<td>Prostate</td>
<td>7.5%</td>
</tr>
<tr>
<td>Non-Hodgkin Lymphoma</td>
<td>5.9%</td>
</tr>
<tr>
<td>Bladder</td>
<td>4.0%</td>
</tr>
<tr>
<td>Myeloma</td>
<td>3.8%</td>
</tr>
<tr>
<td>Pancreas</td>
<td>3.4%</td>
</tr>
<tr>
<td>Kidney and Renal Pelvis</td>
<td>3.2%</td>
</tr>
<tr>
<td>Colon</td>
<td>3.1%</td>
</tr>
<tr>
<td>Corpus Uteri</td>
<td>2.0%</td>
</tr>
<tr>
<td>Other sites+</td>
<td>27.5%</td>
</tr>
</tbody>
</table>

*Includes analytic and non-analytic cases for accession year 2018. **Excludes basal cell and squamous cell carcinoma. + does not include historical case count [n=1852] Source: Cancer Registry
Moffitt Cancer Center Locations

MOFFITT CANCER CENTER
12902 USF Magnolia Drive, Tampa, Florida
Moffitt offers all levels of care for people with cancer and related diseases.

MOFFITT CANCER CENTER AT INTERNATIONAL PLAZA
4101 Jim Walter Boulevard, Tampa, Florida
Moffitt’s satellite facility near International Plaza in Tampa provides expanded and easily accessible patient services.

MOFFITT CANCER CENTER, RICHARD M. SCHULZE FAMILY FOUNDATION OUTPATIENT CENTER AT MCKINLEY CAMPUS
10920 North McKinley Drive, Tampa, Florida
The McKinley center houses an outpatient surgery center, a cutaneous clinic, a breast clinic, breast imaging services, genetic counseling and more.

MOFFITT MALIGNANT HEMATOLOGY AND CELLULAR THERAPY
At Memorial Healthcare System
801 North Flamingo Road, Pembroke Pines, Florida

1-888-MOFFITT (1-888-663-3488) | MOFFITT.ORG
facebook.com/moffittcancercenter | twitter.com/moffittnews